Skip to main content
Premium Trial:

Request an Annual Quote

Waters Defeat in Patent Infringement Suit Casts Shadow on Earnings

NEW YORK, March 25 - A bruising court ruling has set back Waters' year-end financial results and hurt its first-quarter outlook, the company has said.


The proteomics tool shop restated its earnings for the year to $.83 from $1.23 after it said it will spend $75 million in settlement costs after a court found that a business unit had infringed on a patent held by Applied Biosystems and MDS.


Waters also lowered fourth-quarter results to a one-cent loss from a $.39 earning. First-quarter and fiscal 2002 forecasts are now pegged at 2 percent and 7 percent growth, respectively, from 5 percent and 9 percent, respectively, before the ruling.


The firm has said it plans to appeal the decision.


As GenomeWeb reported on March 15, ABI and MDS said they won a patent infringement suit filed against the unit, Micromass UK, and will walk away with $47.5 million in damages.

The Federal District Court in Wilmington, in Delaware, has ruled that Micromass' Quattro Ultima systems infringe ABI's and MDS' US Patent No. 4,963,736.

According to a joint statement released by ABI and MDS, which together have a partnership called ABI/MDS Sciex, the patent covers technology for "triple quadrupole mass spectrometers."


Waters' tools that are affected by the decision accounted for 2.5 percent of the company's 2001 revenue of $859 million.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.